Screener
DexCom DXCM Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 62.5%+3.7pp | 61.5%+2.1pp | 60.1%-0.4pp | 59%-2.7pp | 58.8%-4.0pp | |
| Operating margin | 22.9%+6.9pp | 21.4%+6.2pp | 19.6%+4.7pp | 17.2%+1.3pp | 16%-1.3pp | |
| Net margin | 20.1%+6.8pp | 19.3%+6.4pp | 17.9%+3.7pp | 16%-1.3pp | 13.3%-3.7pp | |
| Returns | ||||||
| Return on equity | 38.5%+15.7pp | 35.6%+11.9pp | 34.5%+6.9pp | 30.6%-1.4pp | 22.8%-6.6pp | |
| Return on invested capital | 56.2%+24.9pp | 45.9%+15.5pp | 38.6%+9.2pp | 46.3%+11.9pp | 31.3%-9.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.7×+0.1× | 0.7×+0.1× | 0.7×0.0× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.7×+0.2× | 1.9×+0.4× | 1.9×+0.4× | 1.6×-0.9× | 1.5×-1.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $6.72+6.6% | $7.51+35.1% | $6.77+32.9% | $6.69+38.7% | $6.30+7.9% | |
| Valuation | ||||||
| Market capitalization | $31.49B+5.3% | $24.17B-9.7% | $25.89B-14.8% | $26.39B-1.8% | $34.34B-23.8% | |
| Price / earnings | 31.5×-20.8× | 26×-24.1× | 31×-21.8× | 36.6×-2.8× | 60.1×-7.5× | |
| Price / sales | 6.3×-0.6× | 5×-1.4× | 5.6×-2.0× | 5.8×-1.0× | 8×-3.5× | |
| Price / book | 12×+0.4× | 8.2×-3.6× | 9.4×-5.0× | 9.7×-3.9× | 13.3×-5.2× |
FAQ
- What are DexCom's profit margins?
- DexCom (DXCM) runs a 62.5% gross margin and a 22.9% operating margin, with a 20.1% net margin.
- Where do DexCom's ratios come from?
- Every ratio is computed from DexCom's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
